C4 Therapeutics Stock Price on September 27, 2024
| CCCC Stock | USD 4.25 0.24 5.99% |
If you're considering investing in CCCC Stock, it is important to understand the factors that can impact its price. As of today, the current price of C4 Therapeutics stands at 4.25, as last reported on the 22nd of November, with the highest price reaching 4.34 and the lowest price hitting 3.91 during the day. C4 Therapeutics retains Efficiency (Sharpe Ratio) of -0.13, which signifies that the company had a -0.13% return per unit of price deviation over the last 3 months. C4 Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm C4 Therapeutics' Variance of 25.66, information ratio of (0.12), and Market Risk Adjusted Performance of (1.61) to double-check the risk estimate we provide.
At present, C4 Therapeutics' Stock Based Compensation To Revenue is projected to increase slightly based on the last few years of reporting. . At present, C4 Therapeutics' Price To Book Ratio is projected to increase based on the last few years of reporting. The current year's Price Fair Value is expected to grow to 1.20, whereas Price To Sales Ratio is forecasted to decline to 12.84. CCCC Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
CCCC |
Sharpe Ratio = -0.1296
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CCCC |
Estimated Market Risk
| 4.96 actual daily | 44 56% of assets are more volatile |
Expected Return
| -0.64 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average C4 Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of C4 Therapeutics by adding C4 Therapeutics to a well-diversified portfolio.
Price Book 1.1782 | Enterprise Value Ebitda (0.42) | Price Sales 8.4074 | Shares Float 54.2 M | Wall Street Target Price 13.7778 |
Related Headline
Monte Rosa Headline on 27th of September 2024
Acquisition by Walker Paul Edward of 2715968 shares of Monte... by Walker Paul Edward
Filed transaction by Monte Rosa Therapeutics 10 Percent Owner. Grant, award or other acquisition pursuant to Rule 16b-3
C4 Therapeutics Valuation on September 27, 2024
It is possible to determine the worth of C4 Therapeutics on a given historical date. On September 27, 2024 CCCC was worth 6.32 at the beginning of the trading date compared to the closed value of 5.89. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of C4 Therapeutics stock. Still, in general, we apply an absolute valuation method to find C4 Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of C4 Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against C4 Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 6.40 | 6.55 | 6.05 | 6.23 | 642,806 | |
09/27/2024 | 6.32 | 6.36 | 5.82 | 5.89 | 615,354 |
| 5.90 | 6.08 | 5.67 | 5.70 | 639,458 |
| Backtest C4 Therapeutics | | | C4 Therapeutics History | | | C4 Therapeutics Valuation | Previous | Next |
C4 Therapeutics Trading Date Momentum on September 27, 2024
| On September 30 2024 C4 Therapeutics was traded for 5.70 at the closing time. The top price for the day was 6.08 and the lowest listed price was 5.67 . The trading volume for the day was 639.5 K. The trading history from September 30, 2024 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 3.23% . The overall trading delta against the current closing price is 8.32% . |
C4 Therapeutics Fundamentals Correlations and Trends
By evaluating C4 Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among C4 Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. CCCC financial account trend analysis is a perfect complement when working with valuation or volatility modules.About C4 Therapeutics Stock history
C4 Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for CCCC is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in C4 Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing C4 Therapeutics stock prices may prove useful in developing a viable investing in C4 Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 49.6 M | 45 M | |
| Net Loss | -115.4 M | -109.6 M |
C4 Therapeutics Quarterly Net Working Capital |
|
C4 Therapeutics Stock Technical Analysis
C4 Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
C4 Therapeutics Period Price Range
Low | November 22, 2024
| High |
0.00 | 0.00 |
C4 Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
C4 Therapeutics November 22, 2024 Market Strength
Market strength indicators help investors to evaluate how C4 Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading C4 Therapeutics shares will generate the highest return on investment. By undertsting and applying C4 Therapeutics stock market strength indicators, traders can identify C4 Therapeutics entry and exit signals to maximize returns
C4 Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for C4 Therapeutics' price direction in advance. Along with the technical and fundamental analysis of CCCC Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of CCCC to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.52) | |||
| Total Risk Alpha | (1.15) | |||
| Treynor Ratio | (1.62) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |